Interestingly, many drugs that are used off-label for the treatment of different cancer subtypes in the pediatric population target EPH/ephrin members: Panobinostat, used in brain tumors and sarcomas targeting EPHB1, EPHB2, and EPHB3; Dasatinib, used in brain tumors targeting EPHB1, EPHB2 [87,112,136], and in neuroblastoma targeting EPHB4 [97]; and Pazopanib and Trametinib targeting EPHA2 in rhabdomyosarcoma [98]. Here, EPHB2 is linked to cancer.